Published in Chest on June 01, 2008
Should anticoagulation be resumed after intracerebral hemorrhage? Cleve Clin J Med (2010) 1.53
Pharmacological effects of Radix Angelica Sinensis (Danggui) on cerebral infarction. Chin Med (2011) 1.00
Cost-effectiveness analysis of mechanical thrombectomy in acute ischemic stroke. J Neurosurg (2009) 0.98
Acute pulmonary embolism. Part 2: treatment. Nat Rev Cardiol (2010) 0.96
Hemorrhagic cardioembolic stroke secondary to a left ventricular thrombus: a therapeutic dilemma. Oman Med J (2013) 0.94
Platelet-leukocyte interactions link inflammatory and thromboembolic events in ischemic stroke. Ann N Y Acad Sci (2010) 0.92
Effects of extracellular DNA on plasminogen activation and fibrinolysis. J Biol Chem (2011) 0.92
Low molecular weight heparin for the treatment of retinal vein occlusion: a systematic review and meta-analysis of randomized trials. Haematologica (2010) 0.91
Pharmacological effects of Salvia miltiorrhiza (Danshen) on cerebral infarction. Chin Med (2010) 0.90
Antiplatelet drugs and the perioperative period: What every urologist needs to know. Indian J Urol (2009) 0.87
Trends in Ambulatory Prescribing of Antiplatelet Therapy among US Ischemic Stroke Patients: 2000-2007. Adv Pharmacol Sci (2012) 0.86
Antiplatelets versus anticoagulants for the treatment of cervical artery dissection: Bayesian meta-analysis. PLoS One (2013) 0.86
Characteristics of carotid atherosclerotic plaques of chronic lipid apheresis patients as assessed by in vivo high-resolution CMR--a comparative analysis. J Cardiovasc Magn Reson (2012) 0.85
Thrombolysis for acute stroke in hemodialysis: international survey of expert opinion. Clin J Am Soc Nephrol (2011) 0.85
Symptomatic venous thromboembolism in Asian colorectal cancer surgery patients. World J Surg (2011) 0.84
Estradiol modulates post-ischemic cerebral vascular remodeling and improves long-term functional outcome in a rat model of stroke. Brain Res (2012) 0.84
Whole blood viscosity assessment issues III: Association with international normalized ratio and thrombocytopenia. N Am J Med Sci (2010) 0.83
Clinical MRI of acute ischemic stroke. J Magn Reson Imaging (2012) 0.83
Optimization of antiplatelet/antithrombotic therapy for secondary stroke prevention. Ann Indian Acad Neurol (2010) 0.82
Blood glutathione S-transferase-π as a time indicator of stroke onset. PLoS One (2012) 0.81
Risk Factors for DVT/PE in Patients with Stroke and Intracranial Hemorrhage. Open Neurol J (2014) 0.81
The carotid plaque imaging in acute stroke (CAPIAS) study: protocol and initial baseline data. BMC Neurol (2013) 0.81
Review of pharmacology and physiology in thrombolysis interventions. Semin Intervent Radiol (2010) 0.81
Deep vein thrombosis after spine operation in prone position with subclavian venous catheterization: a case report. Korean J Anesthesiol (2014) 0.81
Active α-macroglobulin is a reservoir for urokinase after fibrinolytic therapy in rabbits with tetracycline-induced pleural injury and in human pleural fluids. Am J Physiol Lung Cell Mol Physiol (2013) 0.80
Life-threatening postpartum hemolysis, elevated liver functions tests, low platelets syndrome versus thrombocytopenic purpura - Therapeutic plasma exchange is the answer. Indian J Crit Care Med (2011) 0.79
Determinants of antithrombotic choice for patent foramen ovale in cryptogenic stroke. Neurology (2014) 0.78
Oral anticoagulation in elderly patients as secondary prevention of cardioembolic strokes. Int Arch Med (2010) 0.78
Propensity of Withania somnifera to Attenuate Behavioural, Biochemical, and Histological Alterations in Experimental Model of Stroke. Cell Mol Neurobiol (2015) 0.78
Oral anticoagulant-associated intracerebral hemorrhage. J Neurol (2011) 0.77
Pro-urokinase promotes angiogenesis but does not reduce neuronal apoptosis in infarcted cerebral tissue. Neural Regen Res (2014) 0.77
Massive pulmonary thromboembolism and stroke. Case Rep Med (2011) 0.77
Secondary stroke prevention strategies for the oldest patients: possibilities and challenges. Drugs Aging (2009) 0.77
A reversible aptamer improves outcome and safety in murine models of stroke and hemorrhage. Oligonucleotides (2010) 0.76
Supporting Treatment decision making to Optimise the Prevention of STROKE in Atrial Fibrillation: the STOP STROKE in AF study. Protocol for a cluster randomised controlled trial. Implement Sci (2012) 0.76
Association of geographical factors with administration of tissue plasminogen activator for acute ischemic stroke. J Am Heart Assoc (2013) 0.76
Anticoagulant therapy for ischemic stroke: A review of literature. J Res Med Sci (2012) 0.76
Recombinant tissue plasminogen activator for the treatment of acute ischemic stroke. Proc (Bayl Univ Med Cent) (2011) 0.76
Persistent headache after earache. CMAJ (2010) 0.75
Cryptogenic Stroke And Role Of Loop Recorder. J Atr Fibrillation (2014) 0.75
The economic impact of enoxaparin versus unfractionated heparin for prevention of venous thromboembolism in acute ischemic stroke patients. Clinicoecon Outcomes Res (2012) 0.75
Antithrombotics for secondary prevention of noncardioembolic ischaemic stroke. Nat Rev Neurol (2012) 0.75
Recent advances in management of cerebrovascular diseases. F1000 Med Rep (2009) 0.75
Using Large-Scale Linkage Data to Evaluate the Effectiveness of a National Educational Program on Antithrombotic Prescribing and Associated Stroke Prevention in Primary Care. J Am Heart Assoc (2016) 0.75
Modeling the Cost Effectiveness of Neuroimaging-Based Treatment of Acute Wake-Up Stroke. PLoS One (2016) 0.75
Antithrombotic Utilization Trends after Noncardioembolic Ischemic Stroke or TIA in the Setting of Large Antithrombotic Trials (2002-2009). J Vasc Interv Neurol (2015) 0.75
Rate of deep-vein thrombosis and pulmonary embolism during the care continuum in patients with acute ischemic stroke in the United States. BMC Neurol (2013) 0.75
Clopidogrel versus Other Antiplatelet Agents in the Secondary Prevention of Vascular Events in Adults with Cerebrovascular Disease: Clinical and Cost-Effectiveness Analyses. CADTH Technol Overv (2010) 0.75
Management dilemmas in patients with mechanical heart valves and warfarin-induced major bleeding. World J Cardiol (2012) 0.75
Antithrombotic therapy in cardiac embolism. Curr Cardiol Rev (2010) 0.75
Thromboxane A2 synthetase inhibitor plus low dose aspirin : can it be a salvage treatment in acute stroke beyond thrombolytic time window. J Korean Neurosurg Soc (2011) 0.75
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 56.72
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 41.47
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med (2008) 31.57
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 26.95
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25
Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 16.17
Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet (2010) 11.25
The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. JAMA (2013) 10.43
Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet (2014) 10.06
2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol (2014) 9.96
Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med (2001) 8.95
ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med (2003) 8.83
Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.94
Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med (2008) 7.25
Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.12
Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med (2012) 6.60
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med (2008) 6.08
Transient ischemic attack--proposal for a new definition. N Engl J Med (2002) 4.94
Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet (2010) 4.72
Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med (2003) 4.72
Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation (2002) 4.69
Evaluation of patients with pulmonary nodules: when is it lung cancer?: ACCP evidence-based clinical practice guidelines (2nd edition). Chest (2007) 4.49
Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J (2010) 4.31
Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest (2007) 4.29
Ischemic stroke subtype incidence among whites, blacks, and Hispanics: the Northern Manhattan Study. Circulation (2005) 4.08
Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke (2008) 4.06
Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 4.01
Comparison of intravenous alteplase with a combined intravenous-endovascular approach in patients with stroke and confirmed arterial occlusion (RECANALISE study): a prospective cohort study. Lancet Neurol (2009) 3.88
Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest (2004) 3.86
The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 3.74
An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2013) 3.60
A transient ischaemic attack clinic with round-the-clock access (SOS-TIA): feasibility and effects. Lancet Neurol (2007) 3.56
Interventional pulmonary procedures: Guidelines from the American College of Chest Physicians. Chest (2003) 3.55
Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA (2004) 3.51
Statin therapy in the prevention of recurrent cardiovascular events: a sex-based meta-analysis. Arch Intern Med (2012) 3.50
Invasive mediastinal staging of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest (2007) 3.46
Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 3.36
Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest (2007) 3.36
Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 3.31
Periodontal microbiota and carotid intima-media thickness: the Oral Infections and Vascular Disease Epidemiology Study (INVEST). Circulation (2005) 3.25
Predicting long-term outcome after acute ischemic stroke: a simple index works in patients from controlled clinical trials. Stroke (2008) 3.21
Sodium, blood pressure, and cardiovascular disease: further evidence supporting the American Heart Association sodium reduction recommendations. Circulation (2012) 3.14
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J (2011) 3.00
The importance of population-wide sodium reduction as a means to prevent cardiovascular disease and stroke: a call to action from the American Heart Association. Circulation (2011) 2.89
Addition of brain and carotid imaging to the ABCD² score to identify patients at early risk of stroke after transient ischaemic attack: a multicentre observational study. Lancet Neurol (2010) 2.87
An Official ATS/AACN/ACCP/ESICM/SCCM Policy Statement: Responding to Requests for Potentially Inappropriate Treatments in Intensive Care Units. Am J Respir Crit Care Med (2015) 2.86
Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest (2007) 2.83
National Stroke Association guidelines for the management of transient ischemic attacks. Ann Neurol (2006) 2.82
A review of the evidence for the use of telemedicine within stroke systems of care: a scientific statement from the American Heart Association/American Stroke Association. Stroke (2009) 2.74
Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest (2004) 2.74
Evidence for the treatment of patients with pulmonary nodules: when is it lung cancer?: ACCP evidence-based clinical practice guidelines (2nd edition). Chest (2007) 2.72
Forecasting the future of stroke in the United States: a policy statement from the American Heart Association and American Stroke Association. Stroke (2013) 2.66
Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest (2007) 2.60
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol (2007) 2.56
Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 2.56
Atherosclerotic disease of the aortic arch as a risk factor for recurrent ischemic stroke. The French Study of Aortic Plaques in Stroke Group. N Engl J Med (1996) 2.55
Metabolic syndrome and ischemic stroke risk: Northern Manhattan Study. Stroke (2007) 2.55
Statin treatment and stroke outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke (2009) 2.51
Moderate alcohol consumption reduces risk of ischemic stroke: the Northern Manhattan Study. Stroke (2005) 2.51
Diagnosis of DVT: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 2.50
Ideal cardiovascular health predicts lower risks of myocardial infarction, stroke, and vascular death across whites, blacks, and hispanics: the northern Manhattan study. Circulation (2012) 2.48
Initial diagnosis of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest (2007) 2.47